Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Seagen Inc (NQ: SGEN )

212.72 -0.49 (-0.23%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Seagen Inc

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Benzinga's Top Ratings Upgrades, Downgrades For March 24, 2023
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Oak Street Health (NYSE – OSH), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL)
From Brodsky & Smith LLC
Via GlobeNewswire
Why Pfizer Likely Isn't Done With M&A After the Seagen Deal
Pfizer's stock remains down despite its latest dealmaking, but it may only be a matter of time before it starts to rally. 
Via The Motley Fool
Here's How Much You Would Have Made Owning Seagen Stock In The Last 5 Years
Via Benzinga
A Bullish Sign Appears On Seagen's Chart
Via Benzinga
Seagen Inc. (NASDAQ: SGEN) Climbs to New 52-Week High
Via Investor Brand Network
3 Dividend Contenders to Buy Now for Long-Term Gains Later
Dividend stocks have a role to play in any portfolio, and this article highlights three dividend contenders that you can buy now to get long-term gains later 
Via MarketBeat
Pfizer Has Another Blockbuster on the Horizon, but That's Not All
The drugmaker continues to grab headlines for the right reasons. 
Via The Motley Fool
1 Top Healthcare Stock That Could Make You Richer in the Next Decade
The Pfizer of tomorrow will be larger and even more lucrative to hold than it is now. 
Via The Motley Fool
Week In Review: Livzon In-Licenses GERD Therapy In $127 Million Agreement
Livzon Pharmaceutical Group entered a $127.5 million agreement for China rights to a gastroesophageal reflux disease therapy from Onconic Therapeutics. Meanwhile, Gracell Biotech announced that it had... 
Via Talk Markets
MarketBeat Week in Review – 3/13 - 3/17
The first triple witching day of 2023 is a fitting way to end a wild week. As you take some time to relax, here are some of our most popular stories this week 
Via MarketBeat
Topics ETFs Economy
Exposures Interest Rates
Stock Market Diverges Amid Bank Woes, Growth Gains; First Republic, Credit Suisse, Meta In Focus: Weekly Review
A market rally is underway, but bank stocks kept tumbling. 
Via Investor's Business Daily
This Must-Buy Dividend Growth Stock Could Pay You for Life
It might not regularly beat the market, but it won't have any trouble padding your wallet. 
Via The Motley Fool
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time for another dive into the biggest pre-market stock movers as we go over all the latest news for Thursday morning! 
Via InvestorPlace
Pfizer’s Latest Acquisition Strengthens the Case for PFE Stock
Pfizer's merger with Seagen will strengthen the company's already strong oncology portfolio and perhaps boost the case for owning PFE stock 
Via MarketBeat
Benzinga's Top Ratings Upgrades, Downgrades For March 15, 2023
Via Benzinga
Drug Companies Raising Prices Greater Than Inflation? US Government Mulling Imposing Fines
Under Joe Biden's signature Inflation Reduction Act, drugmakers for twenty-seven drugs will be penalized for charging prices that rise faster than inflation for people with disabilities or the elderly... 
Via Benzinga
Meta Platforms To Rally Over 36%? Here Are 10 Other Analyst Forecasts For Wednesday
Credit Suisse cut the price target for Zscaler, Inc. (NASDAQ: ZS) from $275 to $165. Credit Suisse analyst Sami Badri maintained an Outperform rating. Zscaler shares fell 1.9% to $105.95 in pre-market... 
Via Benzinga
Seagen to Present New Clinical and Preclinical Data From Broad Portfolio of Targeted Cancer Therapeutics at the 2023 AACR Annual Meeting
From Seagen Inc.
Via Business Wire
Does This Billion-Dollar Deal Solve Pfizer's Biggest Problem?
Pfizer's planned acquisition of Seagen could be a very important move. 
Via The Motley Fool
Key Inflation Meter Doesn't Show New Signs for Concern and Stocks Begin Shaking Off Instability
(Tuesday Market Open) The first of this week’s three critical data releases, February’s Consumer Price Index (CPI), was pretty much in line with expectations Tuesday, perhaps easing some concerns about... 
Via Benzinga
Is Pfizer Stock a Screaming Buy After Its $43 Billion Seagen Acquisition?
Pfizer's $43 billion Seagen acquisition is a long-term value-creation strategy. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For March 14, 2023
Via Benzinga
These Analysts Boost Price Targets On Seagen Following Acquisition News
Pfizer Inc (NYSE: PFE) agreed to acquire Seagen Inc (NASDAQ: SGEN) for $229 in cash per Seagen share for a total enterprise value of $43 billion. Seagen shares jumped 14.5% to close at $197.65 on... 
Via Benzinga
Jabil To Rally Around 23%? Here Are 10 Other Analyst Forecasts For Tuesday
Raymond James raised the price target for Jabil Inc. (NYSE: JBL) from $84 to $100. Raymond James analyst Melissa Fairbanks maintained a Strong Buy rating. Jabil shares fell 0.7% to close at $81.35 on... 
Via Benzinga
Did Elon Musk Just Put His Skepticism Behind And Warm Up To mRNA Tech That Powers Most COVID-19 Vaccines?
Tesla CEO Elon Musk has been a skeptic of the COVID-19 vaccines and highly critical of Dr. 
Via Benzinga
SEAGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Seagen Inc. - SGEN
From Kahn Swick & Foti, LLC
Via Business Wire
Monday Merger Mania Just Made These 2 Biotech Stocks Big Winners
On a volatile market day, companies are still looking for smart combinations. 
Via The Motley Fool
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Qualtrics (Nasdaq - XM), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL)
From Brodsky & Smith LLC
Via GlobeNewswire
Why Bank Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Provention Bio, Inc. (NASDAQ: PRVB) shares jumped 250.8% to $23.50 after Sanofi announced it will acquire the company for $25 per share in cash. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.